NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-117-2006-0-EP-05 BORIS ISOFORMS AND METHODS OF DETECTING AND TREATING DISEASE EP National Stage 07841646.8 Abandoned
NICHD E-306-2007-0-US-01 Method for the Treatment of HIV/AIDS Infection using Acyclovir in Identified Subjects US 60/966,809 Abandoned
NCI E-326-2007-0-US-01 DIAGNOSTIC TOOL FOR DIAGNOSING BENIGN VERSUS MALIGNANT THRYROID LESIONS US 60/966,271 Abandoned
NIAID E-248-2006-0-EP-07 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus EP DIV 11183527.8 Issued
NIAID E-248-2006-0-FR-23 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus FR EP 11183527.8 Issued
NIAID E-248-2006-0-DK-22 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus DK EP 11183527.8 Issued
NIAID E-248-2006-0-DE-21 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus DE EP 11183527.8 Issued
NIAID E-248-2006-0-NL-25 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus NL EP 11183527.8 Issued
NIAID E-248-2006-0-GB-24 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus GB EP 11183527.8 Issued
NIAID E-248-2006-0-IN-04 INTERGENIC SITES BETWEEN CONSERVED GENES IN THE GENOME OF MODIFIED VACCINIA ANKARA (MVA) VACCINIA VIRUS IN National Stage 1535/DELNP/2009 Issued
NIAID E-248-2006-0-CN-06 "Intergenic Sites Between Conserved Genes in the Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus" CN National Stage 200780035385.3 Issued
NIAID E-248-2006-0-GB-14 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus GB EP 07874019.8 Issued
NIAID E-248-2006-0-CH-09 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus CH EP 07874019.8 Issued
NIAID E-248-2006-0-DK-11 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus DK EP 07874019.8 Issued
NIAID E-248-2006-0-DE-10 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus DE EP 07874019.8 Issued
NIAID E-248-2006-0-FR-13 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus FR EP 07874019.8 Issued
NIAID E-248-2006-0-BE-08 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus BE EP 07874019.8 Issued
NIAID E-248-2006-0-IT-16 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus IT EP 07874019.8 Issued
NIAID E-248-2006-0-IE-15 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus IE EP 07874019.8 Issued
NIAID E-248-2006-0-NL-17 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus NL EP 07874019.8 Issued
NIAID E-248-2006-0-ES-12 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus ES EP 07874019.8 Issued
NIAID E-248-2006-0-EP-03 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus EP National Stage 07874019.8 Issued
NCI E-090-2009-3-PCT-01 Systems And Methods For High Throughput, Minimally-Invasive Radiation Biodosimetry PCT PCT COMB PCT/US2007/076825 Expired
NIAID E-302-2006-1-PCT-01 Epitope-Transplant Scaffolds And Their Use PCT PCT COMB PCT/US2007/076824 Expired
NIDDK E-149-2006-2-PCT-01 COMPOSITIONS AND METHODS FOR MODIFYING CELLULAR PROPERTIES PCT PCT COMB PCT/US2007/018699 Expired
NIAID E-281-2006-0-PCT-02 RNASE a Peptides, Fragments and Uses Thereof PCT PCT PCT/US2007/018690 Expired
NIAID E-302-2006-1-US-03 EPITOPE-TRANSPLANT SCAFFOLDS AND THEIR USE US ORD 12/438,913 Abandoned
NIA E-138-2000-0-US-05 Tumor Markers in Ovarian Cancer US CON 11/895,326 Abandoned
NIAID E-302-2006-1-EP-02 Epitope-Transplant Scaffolds And Their Use EP National Stage 07841376.2 Abandoned
NIAID E-248-2006-0-PCT-02 Intergenic Sites Between Conserved Genes In The Genome Of Modified Vaccinia Ankara (MVA) Vaccinia Virus PCT PCT PCT/IB2007/004575 Expired
NIA E-059-2006-0-PCT-02 METHOD OF TREATING OR PREVENTING OXIDATIVE STRESS-RELATED DISEASE PCT PCT PCT/US2007/076597 Expired
NIA E-059-2006-0-EP-08 Derivatives Of Uric Acid And Thiouric Acide For Oxidative Stress-Related Diseases. EP DIV 13155909.8 Abandoned
NIA E-059-2006-0-EP-05 METHOD OF TREATING OR PREVENTING OXIDATIVE STRESS-RELATED DISEASE EP National Stage 07814379.9 Abandoned
NIA E-059-2006-0-CA-04 METHOD OF TREATING OR PREVENTING OXIDATIVE STRESS-RELATED DISEASE CA National Stage 2661553 Abandoned
NIA E-059-2006-0-AU-03 METHOD OF TREATING OR PREVENTING OXIDATIVE STRESS-RELATED DISEASE AU National Stage 2007286630 Abandoned
NCI E-279-2007-0-PCT-01 ALPHA 1-3 N- GALACTOSYLTRANSFERASE WITH ALTERED DONOR AND ACCEPTOR SPECIFICITIES, COMPOSITIONS, AND METHODS OF USE PCT PCT PCT/US2007/018678 Expired
NCI E-280-2007-0-PCT-01 BETA 1, 4-GALACTOSYLTRANSFERASES WITH ALTERED DONOR AND ACCEPTOR SPECIFICITIES, COMPOSITIONS, AND METHODS OF USE PCT PCT PCT/US2007/018656 Expired
NIAID E-055-2007-2-US-01 Use of Antagonists of the Interaction Between HIV Gp120 And Intregrin US 60/957,140 Abandoned
NCI E-042-2006-4-US-03 Protective Complement Proteins and Age-related Macular Degeneration US National Stage 11/894,784 Abandoned
NIA E-005-2008-0-US-01 REGULATION OF RELEASE OF GLP-I AND SGLT-l FROM ENTEROENDOCRINE CELLS IN RESPONSE TO AGENTS ACTING ON TASTE SIGNALING MOLECULES In THE Gut US 60/695,463 Abandoned
NIAID E-022-2008-2-US-02 MOLECULAR SCAFFOLDS FOR HIV-1 IMMUNOGENS US National Stage 11/816,624 8647818 Expired PDF
NCI E-198-2006-0-PCT-02 Anti-H5N1 Influenza Activity Of The Antiviral Protein Cyanovirin-N (CV-N) PCT PCT PCT/US2007/076181 Expired
NIMH E-281-2005-0-US-03 BACTERIOPHAGE/QUANTUM-DOT (PHAGEQD) NANOCOMPLEX TO DETECT BIOLOGICAL TARGETS IN CLINICAL AND ENVIRONMENTAL ISOLATES US National Stage 11/884,604 Abandoned
NCI E-237-2007-0-US-01 HYDRAZIDE, AMIDE, PHTHALIMIDE AND PHTHALHYDRAZIDE ANALOGS AS INHIBITORS OF RETROVIRAL INTEGRASE US 60/956,636 Abandoned
NIAID E-304-2007-0-US-01 Use Of Chimeric HIV/SIV Gag Proteins To Optimize Vaccine-Induced T Cell Responses Against HIV Gag US 60/965,268 Abandoned
NHLBI E-322-2007-0-US-01 Compositions containing purine nucleoside and manganese and their uses US 60/935,494 Abandoned
NINDS E-182-2007-0-US-01 Methods for Promoting Stem Cell Proliferation and Survival US 60/965,094 Abandoned
NCI E-227-2006-4-US-01 INCREASING BLOOD FLOW AND TISSUE HEALING IN THE ELDERLY US 60/956,375 Abandoned
NIAID E-139-2006-0-CA-64 Development Of Dengue Virus Vaccine Components CA DIV 3004991 Issued
NIAID E-139-2006-0-CA-05 Development Of Dengue Virus Vaccine Components CA National Stage 2661296 Issued